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siRNA screenpathogens, especially viruses, is intimately tied to the macromolecular synthetic
processes of their host cell. In the case of positive-stranded RNA viruses, the ability to translate and, thus,
replicate their infecting genome is dependent upon hijacking host proteins. To identify proteins that
participate in West Nile virus (WNV) replication, we tested the ability of siRNAs designed to knock-down the
expression of a large subset of human genes to interfere with replication of WNV replicons. Here we report
that multiple siRNAs for proteasome subunits interfered with WNV genome ampliﬁcation. Speciﬁcity of the
interference was shown by demonstrating that silencing proteasome subunits did not interfere with
Venezuelan equine encephalitis virus replicons. Drugs that blocked proteasome activity were potent
inhibitors of WNV genome ampliﬁcation even if cells were treated 12 h after infection, indicating that the
proteasome is required at a post-entry stage(s) of the WNV infection cycle.
© 2008 Elsevier Inc. All rights reserved.IntroductionThe genus Flavivirus, within the family Flaviviridae, consists of
multiple viruses of particular importance to public health, including
yellow fever virus, Japanese encephalitis virus, dengue virus andWest
Nile virus (WNV). These viruses are responsible for signiﬁcant
morbidity and mortality worldwide. WNV ﬁrst became a public
health concern in the United States in 1999, when it was introduced
into New York City. Since then, there have been more than 27,000
reported cases of disease associated with WNV infection with over
11,000 cases presenting with severe neurological pathologies, result-
ing in nearly 1200 deaths (Centers for Disease Control and Prevention,
2008). Unfortunately, as with many other ﬂaviviruses, there are no
approved antiviral therapies to control WNV disease and, as of yet, no
approved vaccine for protection against WNV diseases.
Similar to other members of the genus, the WNV genome consists
of a positive-sense, single-stranded RNA approximately 11 kilobases in
length. The genome encodes a mere 11 proteins, 3 nonstructural (C,
prM/M and E) and seven nonstructural (NS1–NS5) (Brinton, 2002), all
of which has been demonstrated to play some role in replication of the
viral genome (Lindenbach et al., 2007). Due to the limited amount of
genetic material it carries, WNV, like other viruses, is expected to beedical Branch, 301 University
09 747 8150.
l rights reserved.dependent uponmany components of themacromolecular machinery
of the host cell. As a consequence, it is expected that WNV proteins
and the viral genome must interact with a multitude of host proteins
to infect cells and efﬁciently reproduce itself. In fact, several such
interacts at various stages of WNV infection have been identiﬁed.
One of the ﬁrst virus–host interactions that can occur is the
interaction between the virus particle and a receptor(s) on the host
cell surface to promote viral entry. A recent report suggests that WNV
entry may be mediated, in part, by αvβ3 integrin (Chu and Ng, 2004b)
or DC-SIGN (Davis et al., 2006) resulting in internalization of the virus
via a clathrin-dependent endocytic pathway (Chu and Ng, 2004a).
Further, infection of the virus can also be facilitated by binding to cell-
surface heparan sulfate (Gilfoy and Mason, 2007; Lee and Lobigs,
2000). Three different host proteins, translation elongation factor-1α,
T cell intracellular antigen-1 (TIA-1) and TIA-1-related protein (TIAR)
have been shown to interact with the 3′-terminal stem loop of the
WNV genome (Blackwell and Brinton, 1995; Blackwell and Brinton,
1997; Li et al., 2002). The interaction between TIA-1 and TIAR and
WNV is reported to interfere with WNV-induced stress granule
formation and processing body assembly (Emara and Brinton, 2007),
which are sites of translational control and mRNA aggregation and
degradation under times of stress. Additionally, the Src kinase c-Yes
was demonstrated to be an important host protein involved in WNV
particle release from infected cells, an activity that appears tomanifest
itself at the level of particle trafﬁcking from the endoplasmic
reticulum to the extracellular space (Hirsch et al., 2005).
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protein degradation system that clears unneeded proteins from both
the cytosol and the nucleus. It plays a key role in a vast number of
normal cellular processes including the removal of misfolded or
abnormal proteins, the cellular stress response, the removal of
unneeded proteins during cell differentiation, cell cycle regulation
and the cellular immune response (Ciechanover, 1994; Glickman and
Ciechanover, 2002). Proteins targeted for degradation are tagged with
ubiquitin by a covalent bond that is produced by three enzymatic
entities: an activating enzyme, E1, a carrier enzyme, E2, and a ligase,
E3, which ultimately binds ubiqutin onto the protein (Glickman and
Ciechanover, 2002; Nandi et al., 2006). Mono- or polyubiquinated
proteins are then trafﬁcked to the 26S proteasome, where they are
degraded.
The eukaryotic 26S proteasome is a ubiquitous, highly conserved
multi-protease complex consisting of a barrel-shaped, proteolytic core
complex (the 20S proteasome) with a 19S regulatory complex, or cap,
at one or both ends (Groll et al., 1997; Perkins et al., 1994; Tanaka et al.,
1988; Voges et al., 1999). The 20S proteasome is composed of two
copies of seven alpha subunits (α1–α7) and seven beta subunits
(β1–β7) arranged into 4 stacked rings. The two outer rings contain the
alpha subunits, which are important for controlling entry and exit of
proteins as well as binding to speciﬁc regulatory proteins. The two
inner rings, on the other hand, are composed of the beta subunits,
which represent the catalytic active sites of the proteasome (Nandi
et al., 2006). Up to three primary proteolytic activities have been
attributed to the proteasome: trypsin-like activity (cleavage after
hydrophobic amino acids), chymotryspin-like activity (cleavage after
the basic amino acids) and caspase-like (cleavage after the acidic
amino acids). In eukaryotic proteasomes, each of these protease
activities is associated with a speciﬁc beta subunit, β2, β5 and β1,
respectively (Dick et al., 1998; Kisselev et al., 2003; Nussbaum et al.,
1998). Interestingly, in mammals a specialized form of the proteasome
has evolved in which the three catalytic beta subunits are replaced by
different catalytic subunits, β2i, β5i and β1i (Demartino and Gillette,
2007). This proteasome, referred to as the immunoproteasome,
replaces the constitutive proteasome following immune stimulation
and is responsible for generating antigenic peptides that are displayed
by the class I major histocompatability complex {MHC I (Baumeister et
al., 1998; Goldberg et al., 2002; Rock et al., 1994)}.
The life cycle of viruses is intimately tied to the life cycle of the
cells; therefore, it is unsurprising that viruses have evolved mechan-
isms to both hinder the host's response and parasitize host functions
in their own replication. Members of multiple families of both RNA
and DNA viruses have been shown to modulate the ubiquitin–
proteasome system to their advantage for a variety of reasons,
including immune evasion, viral entry or release, transcriptional
regulation and apoptosis inhibition (Banks et al., 2003; Gao and Luo,
2006; Shackelford and Pagano, 2005). Many viruses, including human
cytomegalovirus (Kikkert et al., 2001; Shamu et al., 2001), Epstein Barr
virus (Levitskaya et al., 1997) and several other herpes viruses
(Boname and Stevenson, 2001; Coscoy et al., 2001) interfere with
the processing of MHC class I peptides. The ubiquitin–proteasome
system has been shown to facilitate entry or transport of incoming
inﬂuenza virus (Khor et al., 2003), minute virus (Ros et al., 2002; Ros
and Kempf, 2004) and murine coronavirus (Yu and Lai, 2005). The
release of HIV viral progeny requires proteasome activity, presumably
by allowing efﬁcient processing of Gag protein by the viral protease,
thereby facilitating virion budding from the plasma membrane
(Patnaik et al., 2000; Schubert et al., 2000; Strack et al., 2000).
Additionally, proteasome inhibition markedly reduces coxsackievirus
group B3 viral RNA and protein synthesis levels, resulting in a decrease
in the release of progeny virus (Luo et al., 2003).
Here we demonstrate that WNV genome ampliﬁcation (either
genome replication or genome translation) is sensitive to disruption of
proteasome function. In a large-scale siRNA screen of human genes,we discovered that silencing two different alpha subunits of the 26S
proteasome with siRNAs, PSMA1 and PSMA2, resulted in a dramatic
reduction in WNV genome-driven ﬁreﬂy luciferase (FLuc) activity.
Additionally, using speciﬁc proteasome inhibitors, MG132 and PS1, we
demonstrate that inhibition of the proteasome results in a reduction
of WNV antigen levels, WNV protein accumulation and progeny virus
yield. This inhibition is observed following treatment with these
inhibitors both pre- and post-infection, indicating that WNV utilizes
the proteasome at a post entry step of its replication cycle.
Results
Silencing proteasome subunits results in a reduction in WNV FLuc, but
not VEEV FLuc, activity
To aid in identifying host proteins that facilitate WNV infection
and/or genome ampliﬁcation, a library of siRNAs was screened for its
ability to suppress ﬁreﬂy luciferase (FLuc) signal encoded by WNV
viral replicon particles (VRPs) (Fayzulin et al., 2006). VRPs are
replicons (viral genomes lacking the sequences for the structural
genes) packaged into particles with structural proteins that are
provided in trans by packaging cells. WNV VRPs are particularly useful
as they mimic WNV infection and genome ampliﬁcation in nearly all
aspects; however, because the packaged replicons do not encode the
structural genes, VRP infections do not produce progeny virions. Thus,
VRPs can be used to easily study infection and/or genome ampliﬁca-
tion independent of assembly and release. Additionally, because they
are unable to spread beyond the initially infected cell, VRPs are safe to
use under biosafety level 2 (BSL2) conditions.
The siRNA library utilized for these studies was a human druggable
genome library purchased from Ambion that consisted of 3 individual
siRNAs designed to silence approximately 5500 genes. Huh7 cells
stably expressing Renilla luciferase (RLuc) were transfected with each
siRNA (30 μM), infected with the WNV VRP expressing FLuc (WNV
FLuc VRP) 72 h later, and then assayed for both FLuc (WNV VRP
infection/genome ampliﬁcation) and RLuc (cell number) activity 24 h
post infection. These studies identiﬁed 50 candidate genes for which
transfection of 2 of the 3 individual siRNAs into Huh7 cells resulted in
a greater than 60% reduction in RLuc-normalized WNV-dependent
FLuc activity and did not result in a reduction in RLuc activity of
greater than 40% (data to be published elsewhere).
To validate the 50 candidate genes obtained from screening the
5500 gene library, several conﬁrmatory tests were performed utilizing
the siRNAs corresponding to these 50 genes. The three individual
siRNAs for each of the 50 genes were assayed for inhibition of WNV
FLuc VRP activity in 3 additional human cell lines (HeLa, Hec1B and
SK-N-SH cells), and also tested for their ability to reduce β-
galactosidase (β-gal) activity encoded by a WNV β-gal VRP (Fayzulin
et al., 2006) and to reduce antigen synthesis by ‘live’ WNV. To ensure
that the candidate genes were important speciﬁcally for WNV
infection, siRNA-transfected cells were infected with a FLuc-encoding
Venezuelan equine encephalitis virus (VEEV) VRP and tested for the
ability of the siRNAs to inhibit the infection and/or genome
ampliﬁcation of this alphavirus. As a ﬁnal conﬁrmation, pools of 4
individual siRNAs targeted against each candidate gene were
purchased from a second source (Dharmacon) and assayed in the
Huh7 cells. These secondary screens resulted in approximately 10
conﬁrmed candidate genes (data to be published elsewhere).
Interestingly, 2 of these 10 conﬁrmed candidate genes were
subunits of the proteasome. In fact, 2 of 3 individual siRNAs (Ambion)
and the pools of 4 siRNAs (Dharmacon) targeted against two alpha
subunits, PSMA1 and PSMA2, were shown to consistently reduceWNV
infection or genome ampliﬁcation (N60% decrease in RLuc-normalized
FLuc activity) when transfected into cells with little or no effect on cell
number. Fig. 1A shows an example of a typical silencing experiment
showing that transfection of a pool of 4 siRNAs (Dharmacon) targeted
Fig. 1. Silencing PSMA1 or PSMA2 result in a decrease in WNV-induced FLUC activity.
(Panel A) Non-targeting, negative control (NEG) siRNA, WNV-speciﬁc, FLuc-speciﬁc,
PSMA1-speciﬁc or PSMA2-speciﬁc siRNAs were transfected into Huh7 cells, incubated
for 72 h and then infected with VEEV FLuc VRP or WNV hFLuc VRP for an additional 16
or 24 h, respectively. Cell monolayers were then assayed for FLuc activity (WNV or VEEV
replication levels) and RLuc activity (cell number). Values are shown as % FLuc
normalized to % RLuc compared tomock-transfected cells. Error bars represent standard
deviations from the mean between three independent experiments and an asterisk
represents statistic signiﬁcance compared to NEG siRNA transfection (pb0.05). (Panel B)
Monolayers of siRNA-transfected Huh7 cells were harvested and assayed, by Western
blot, for levels of PSMA1, PSMA2, WNV NS3 and β-actin (loading control).
76 F. Gilfoy et al. / Virology 385 (2009) 74–84against either PSMA1 or PSMA2 dramatically lowered WNV replicon-
driven FLuc activity compared to cells transfected with a non-
targeting control siRNA (NEG; Fig. 1A). However, VEEV replicon-
driven FLuc activity was not impaired following transfection with
either PSMA1 or PSMA2-speciﬁc siRNA (Fig. 1A), indicating the
speciﬁcity of the siRNA interference. Additionally, although FLuc-
speciﬁc siRNAs reduced FLuc expression derived from both WNV and
VEEV VRPs, siRNAs targeted against the WNV genome were, as
expected, speciﬁc for WNV replicon-driven FLuc activity (Fig. 1A).
Transfection with PSMA1 or PSMA2 siRNAs also resulted in a greater
than 60% reduction in WNV antigen expression following ‘live’ WNV
infection (data not shown).
To conﬁrm the effectiveness of the siRNAs, Western blot analysis
was performed on the siRNA-transfected cell lysates. Analysis
indicated that transfection of PSMA1 or PSMA2 siRNA resulted in
reduced PSMA1 and PSMA2 expression, respectively, compared to
NEG control or WNV-speciﬁc siRNA transfection (Fig. 1B). Interest-
ingly, transfection of either PSMA1-speciﬁc or PSMA2-speciﬁc siRNAs
resulted in decreased expression of both subunits, although the
expression of the speciﬁc target gene always demonstrated greater
knockdown. Even so, the silencing of one subunit had an effect on the
steady state levels of the other subunit of the proteasome, possibly
through the destruction of subunits that are not stabilized by their
assembly into the multi-molecule complex or by the ability of one ormore of the siRNAs targeted against PSMA1 will also partially
recognize PSMA2, and vice versa.
To demonstrate a corresponding decrease in WNV antigen
expression following the silencing of PSMA1 or PSMA2, membranes
were also probed with a WNV-speciﬁc antibody. Results showed a
dramatic reduction in the expression of WNV NS3 following
transfection with PSMA1, PSMA2 or WNV siRNAs compared to
transfection with the NEG siRNA (Fig. 1B).
Pre-treatment of cells with proteasome inhibitors results in reduced
WNV genome ampliﬁcation and protein expression
SiRNA technology is a powerful tool for studying gene function;
however, due to the potential for off-target silencing effects
(Birmingham et al., 2006; Jackson et al., 2003; Lin et al., 2005; Qiu
et al., 2005; Scacheri et al., 2004), we validated our results by treating
Huh7 or HeLa cells with two different proteasome inhibitors, MG132
and PS1, both of which are potent, cell-permeable, reversible
inhibitors of the chymotrypsin-like activity of the 20S proteasome
(Borissenko and Groll, 2007).
The cells were treated with MG132 or PS1, infected with WNV
hFLuc VRP and then assayed for FLuc activity, WNV antigen
accumulation (ELISA) and cell viability. Cell viability/cell number
was measured by two methods: the MTT assay and an assay for cell-
expressed RLuc activity. To simplify presentation of the results only
the MTT values are shown, although RLuc activity correlated well with
the MTT values in all cases.
HeLa cells pre-treated with as little as 0.3 μM of MG132 showed a
marked reduction in both WNV-driven FLuc activity and WNV ELISA
antigen expression compared to mock- or DMSO-treated cells (Fig.
2A). Additionally, treatment with as little as 0.08 μM of PS1 (Fig. 2B)
resulted in a greater than 70% inhibition in WNV activity compared to
the DMSO vehicle treatment. Although the inhibitors appeared to be
less effective at inhibiting WNV VRP infection/genome ampliﬁcation
in Huh7 cells compared to HeLa cells, treatment with bothMG132 and
PS1 resulted in substantially lower FLuc activity and WNV ELISA
antigen expression compared to mock or DMSO treatment. Treatment
with MG132, which was more effective than PS1 in these cells, led to a
greater than 80% reduction in WNV activity with as little as 1.25 μM
(Fig. 2C) while pre-treatment with PS1 at this same concentration
resulted in an approximate 60% reduction in WNV activity (Fig. 2D).
Consistent with the inability of PSMA-speciﬁc siRNAs to impair VEEV
VRP-driven FLuc activity, MG132- or PS1-treated Huh7 cells demon-
strated little or no reduction in VEEV VRP-driven FLuc activity
compared to mock-treated cells (data not shown). Throughout these
experiments, only the highest concentration (20 μM) of MG132 and
PS1 in either Huh7 or HeLa cells resulted in any major changes in
cellular characteristics or a reduction in cell viability, measured by
either MTT assay (Figs. 2A–D) or RLuc activity (results not shown).
To monitor WNV antigen expression by another method and to
help ensure the speciﬁcity and sensitivity of the ELISA assay, PS1- or
MG132-treated HeLa cells were infected with WNV hFLuc VRPs and
then the cell monolayers were harvested and assayed for NS3
expression by Western blot analysis. Consistent with the Fig. 2
studies, treatment of HeLa cells with PS1 resulted in a reduction in
WNV protein expression at the lowest drug doses tested (Fig. 3A).
Additionally, treatment with MG132 resulted in a reduction in WNV
protein expression compared to mock- or DMSO-treated cells,
although, consistent with our FLuc and ELISA detection methods
(see Fig. 2) the MG132-mediated effect on NS3 expression was less
than that observed with PS1 treatment (Fig. 3B). The NS3 antibody
consistently recognized two bands. The lower band corresponds to
the predicted molecular weight of NS3, approximately 70kd, while
the top band may represent uncleaved NS2A–NS3 or NS3–NS4A.
Levels of β-actin, which served as a loading control, were similar in
all treatment groups with the exception of 20 μM MG132, where a
Fig. 2. Pre-treatment of cells with proteasome inhibitors impairs WNV infection/replication. HeLa cells (panels A–B) and Huh7 cells (panels C–D) were pre-treated with the indicated
concentrations (0, 0.08, 0.31, 1.25 or 20 μM) of either MG-132 (panels A, C) or PS1 (panels B, D) prior to WNV hFLuc VRP infection and then assayed for FLuc activity, WNV ELISA
antigen expression or cell viability (measured by MTT assay, see Materials and methods). Values are shown as percent of WNV VRP-infected, mock-treated cells and error bars
represent standard deviation from the mean between three independent experiments.
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observed with this dose. IFA performed on proteasome inhibitor-
treatedHeLa cellswas consistentwith theWestern blot analysis (Fig. 4).
PS1 andMG132 treatment inHeLa cells reduced the detectable levels of
both NS1 (Fig. 4A) and NS3 (Fig. 4B), although PS1 appeared to bemore
effective than MG132, consistent with our previous studies. Inter-
estingly, both PS1 andMG132 appeared to bemore effective at blocking
NS1 protein accumulation than NS3, although the signiﬁcance of this is
not known (Fig. 4). IFA performed on proteasome inhibitor-treated
Huh7 cells showed a similar reduction in both NS1 and NS3 levels
(results not shown). DAPI and phalloidin counterstains indicated that
inhibitor-treated cells did not have any nuclear abnormalities or any
major defects in their overall cellular architecture, arguing against a
non-speciﬁc effect of the inhibitor on WNV genome ampliﬁcation.
Since both MG132 and PS1 are reversible inhibitors of the
proteasome, it was possible to determine whether removing inhibitor
treatment from cells would return WNV infection/genome ampliﬁca-
tion to levels observed in mock-treated cells. This type of experiment
helps to ensure that the inhibitor treatment did not result in any
permanent damage to other cellular processes which might be
responsible for the inhibitor-induced inhibition of WNV VRP infection
or genome ampliﬁcation. To this end, Huh7 and HeLa cells were pre-
treated with MG132 or PS1 for approximately 2 h, after which the
drugs were removed. The cells were then infected with WNV hFLuc
VRPs following a 2 h ‘recovery’ period.
Consistent with Fig. 2, Huh7 (Fig. 5A) and HeLa (Fig. 5B) cells that
were incubated with MG132 or PS1 demonstrated a dose-dependent
reduction in WNV-dependent FLuc activity and WNV ELISA antigen
accumulation. However, WNV hFLuc VRP infection/replication in both
Huh7 (Fig. 5A) and HeLa (Fig. 5B) cells in which the MG132 and PS1
treatments were washed off was nearly identical to mock- or DMSO-treated cells for all doses of the inhibitors. These data suggest that
treatment with the inhibitors did not have an indirect effect on the
cell's ability to support WNV VRP genome ampliﬁcation.
Inhibition of the proteasome post-infection reduces WNV
genome ampliﬁcation
To ascertain whether the proteasome inhibitors were serving to
blockWNV VRP at entry or at a later stage of infection, HeLa cells were
treatedwithMG-132 or PI-1 either concurrently withWNV hFLuc VRP
infection or at various times post-infection and then assayed forWNV-
dependent FLuc activity andWNV antigen accumulation. Surprisingly,
treatment with the inhibitors (either MG-132 or PI-1) as late as 12 h
post infection resulted in a reduction in WNV-dependent FLuc and
antigen accumulation (Figs. 6A, B). In fact, at 0 and 2 h post-infection,
the inhibition of WNV activity was nearly to the same extent observed
when the drugs were added prior to infection. However, the inhibitory
effect of these inhibitors on WNV genome ampliﬁcation appears to
wane at the later times post-infectionwith only a 50–60% reduction in
WNV activity at 12 h post infection for all but the highest doses of each
of the drugs (Fig. 6). Consistent with pre-treatment studies, PS1
treatment (Fig. 6B) was more effective than MG132 at all timepoints
tested (Fig. 6A).
Proteasome inhibition results in a reduction of WNV reproduction
Although WNV VRPs mimic WNV infection, it was important to
examine the effect of proteasome inhibitor treatment on ‘live’ WNV
infection, as well. Since proteasome inhibitor treatment had no effect
on the ability of WNV hFLuc VRPs to infect cells, monolayers of HeLa
cells were infected withWNV for 1 h prior to MG132 or PS1 treatment
Fig. 3. Inhibition of proteasome results in reduction in the accumulation of WNV
proteins. Monolayers of HeLa cells were treated with PS1 (panel A) or MG132 (panel B)
at concentrations of 20, 5, 1.25, 0.31, 0.08, 0 μM or DMSO alone for 1 h prior to infection.
Following a 24 hWNV hFLuc VRP infection, Western blot analysis was performed on the
cell lysates. Membranes were probed for WNV NS3 and β-actin, which served as a
loading control.
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Titrations performed on supernatants harvested from the treated cells
indicated that proteasome inhibitor treatment dramatically reduced
the production of infectious WNV particles (Fig. 7). MG132 treatment
of HeLa cells, as observed in WNV VRP experiments, was slightly less
effective at impairing WNV production compared to PS1 treatment;
however, the treated cells still demonstrated a near 80% reduction in
secreted infectious particles compared to mock-treated cells with as
little as 0.16 μM (Fig. 7). PS1, on the other hand, demonstrated
inhibition ofWNV particle release similar toMG132 at a concentration
of only 0.032 μM (Fig. 7). The inhibition ofWNV release was consistent
with the inhibition of WNV VRP-induced FLuc activity and WNV
antigen accumulation. These data indicate that inhibiting proteasome
activity in these cell lines severely impairs the WNV genome
ampliﬁcation, suggesting that the proteasome is an important cellular
co-factor during WNV replication.
Discussion
Many RNA viruses require speciﬁc host factors for efﬁcient
replication.WNV is no exception. Beyond the host machinery required
for entry and translation, such as receptors present on the cell surface
(Chu and Ng, 2004b; Davis et al., 2006; Medigeshi et al., 2008),
acidiﬁcation of endosomes (Chu and Ng, 2004a) and translation
factors (Davis et al., 2007), WNV likely requires additional host
proteins to establish an environment permissive for efﬁcient replica-
tion. For example, the interaction between WNV 3′ stem loop
structure and two host proteins, TIA-1 and TIAR (Li et al., 2002), has
been shown to interfere with the cell's ability to form stress granules,
effectively preventing the host cell from shutting down viral and
cellular translation (Emara and Brinton, 2007). Herewe report that theFig. 4. Proteasome inhibition reduces levels of NS1 and NS3 in HeLa cells. IFA of proteasome in
or MG132 (4 μM) and then infected withWNV hFLuc VRPs. Twenty-four hours post infection
stained monolayers were counterstained for nuclei (blue) and actin (red). NS1 and NS3 areproteasome may serve as an essential co-factor during the WNV
replication cycle.
The ubiquitin–proteasome system is the primary mechanism for
intracellular, extralysosomal protein degradation. It plays a key role in
a variety of cell functions, including cell cycle regulation, antigen
processing, transcriptional regulation, apoptosis, signal transduction
and transcriptional regulation (Ciechanover, 1994; Glickman and
Ciechanover, 2002; Goldberg et al., 2002; Nandi et al., 2006). Because
of its involvement in a vast array of functions, it is not surprising that
multiple viruses have evolved mechanisms to manipulate this system
to its own advantage. Inﬂuenza virus has been shown to utilize the
ubiquitin–proteasome system for efﬁcient trafﬁcking through the late
endosome/lysosome stages of virus entry (Khor et al., 2003). Mouse
hepatitis virus (a coronovirus) and minute virus (a parvovirus) have
also been shown to utilize the proteasome system for trafﬁcking to the
cytoplasm (Yu and Lai, 2005) or the nucleus (Ros et al., 2002; Ros and
Kempf, 2004), respectively. Multiple members of the Herpesviridae
family have evolved different mechanisms to manipulate the ubiqui-
tin–proteasome pathway, whether it is by encoding ubiquitin ligase-
like proteins (Coscoy et al., 2001) or by targeting speciﬁc proteins for
destruction (Coscoy et al., 2001; Kikkert et al., 2001; Parkinson et al.,
1999; Prosch et al., 2003). Inhibition of proteasome activity was shown
to impair coxsackievirus B3 replication (Luo et al., 2003). A recent
report indicated that coxsackievirus-induced activation of the extra-
cellular signal-regulated kinase (ERK) pathway,which is required for its
replication (Luo et al., 2002), is reduced following proteasome
inhibition (Wong et al., 2007), suggesting a possible mechanism of
proteasome action. The ubiquitin–proteasome pathway also appears to
be a critical factor in the lifecycle of HIV, as well. Efﬁcient processing of
Gag polyprotein – and subsequent release and maturation of HIV
particles – is dependent upon ubiquitin–proteasome activities (Patnaik
et al., 2000; Schubert et al., 2000; Strack et al., 2000).
In this study, we describe some of the results from our attempts to
identify novel host factors involved in WNV infection and/or genome
ampliﬁcation. Our studies were based on an unbiased screen of host
factors, systematically knocking down nearly 5500 human genes
using a library of siRNAs. Throughout the initial screening process, and
multiple conﬁrmatory screens, silencingmultiple different subunits of
the proteasome dramatically reduced WNV infection and/or genome
ampliﬁcation. In fact, siRNAs targeted against two alpha subunits,
PSMA1 and PSMA2, consistently knocked down WNV VRP infection
and/or genome ampliﬁcation levels by greater than 70% compared to
non-targeting negative control siRNAs. A similar screen performed
with live WNV also showed that silencing proteasome subunits has a
negative effect on WNV infection/genome ampliﬁcation (Krishnan
et al., 2008). Consistent with these results showing that post-
translational silencing of two proteasome genes could impair WNV
replication, we showed that treatment of cells with micromolar
concentrations of two well-characterized proteasome inhibitors
(MG132 and PS1) resulted in impaired the activity of WNV VRPs and
liveWNV, indicating that a functional proteasome is required forWNV
genome ampliﬁcation.
The small number of candidate genes identiﬁed (less than 0.2%
following all conﬁrmatory tests) was somewhat startling. However,
the library consisted of a relatively small subset of genes (5500 genes
from the 30,000 genes encoded by the human genome) which are
currently known to be involved in many different disease processes.
Even within this subset of genes, it is very likely that many were
overlooked, due to the presence of compensatory pathways, the
expression of homologues or the failure of speciﬁc siRNAs to
efﬁciently silence their target. Although silencing many different
proteasome subunits had an effect onWNV activity in the initial siRNAhibitor-treated HeLa cells. Monolayers of HeLa cells were treated with either PS1 (4 μM)
, the monolayers were ﬁxed and assayed for levels of NS1 (panel A) or NS3 (panel B). The
shown in green.
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Fig. 5. Removing proteasome inhibitors restoresWNV infection/replication. Huh7 cells (panel A) or HeLa cells (panel B) were treatedwith 20, 5, 1.25, 0.31, 0.08, 0 μMMG132 or PS1 for
2 h, and then the drugs were removed and the cells were infected with WNV VRPs. Cells were assayed for FLUC activity, WNV antigen expression and cell viability. Values shown as
percent of mock and error bars represent standard deviation from the mean between three independent experiments.
80 F. Gilfoy et al. / Virology 385 (2009) 74–84library screen we performed, PSMA1 and PSMA2 were the only two
genes to consistently knockdown WNV activity in all secondary
screens. This was puzzling; however, we believe that this is likely due
to the quality of the siRNAs in the initial library. As mentioned above,
not all siRNAs are equally effective, especially the ‘ﬁrst-generation’
siRNAs (which were not optimized or modiﬁed to enhance their
activity) used in the initial siRNA library. Thus, it is likely that the
siRNAs for other proteasome subunits were either not as speciﬁc or as
effective at silencing their target gene compared to PSMA1 and PSMA2
siRNAs. Because the proteasome is composed of many different
subunits we hadmultiple opportunities to silence its expression. Thus,
it appears that this type of multisubunit complex is particularly well
suited for discovery with function-based siRNA screening strategies.
As discussed in the Introduction, viruses have been shown to
manipulate the ubiquitin–proteasome pathway to enhance viral
activities at various stages of the virus lifecycle, including entry and
post-entry trafﬁcking, translation, transcription, and maturation/
release. Post-treatment of WNV VRP-infected cells with MG132 and
PS1 severely impaired WNV VRP genome ampliﬁcation, indicating
that the proteasome was not required for viral entry. In fact, both
MG132 and PS1 were effective inhibitors of WNV VRP activity up to
12 h post infection, suggesting that it is unlikely that the proteasome is
required for the endosomal trafﬁcking of WNV particles or the
uncoating the viral RNA, as it has been shown for inﬂuenza (Khor et al.,
2003) and mouse hepatitis virus (Yu and Lai, 2005). The timing of theWNV life cycle is not well established and is expected to vary between
cell types. The process of viral entry and genome unpackaging likely
occurs within the ﬁrst 2 h. Because WNV is a positive-stranded RNA
virus, the newly unpackaged genome can be transported to cellular
membranes and immediately be translated by cellular machinery.
Once the viral proteins are produced to sufﬁcient levels, the
replication complex can be formed and begin replicating the viral
genome, which serves as a source for more templates for translation.
In some cell types, we have detected low levels of WNV antigen as
little as 12 h post infection, suggesting the presence of active
translation and, likely, replication at this time point. Although we do
not know precisely how the proteasome is involved in the lifecycle, its
effectiveness up to 12 h post infection suggests it is acting at the level
of either translation or genome replication.
We have shown that proteasome inhibition results in a reduction
in WNV yield, however, we have not tested whether, as seenwith HIV
(Martin-Serrano, 2007; Schubert et al., 2000; Strack et al., 2000), the
proteasome is directly involved in the packaging and/or release of
WNV progeny virions. Our studies do not exclude the possibility that
the proteasome is involved at these stages of infection; however, our
initial studies demonstrating impairment in WNV genome ampliﬁca-
tion were performed with WNV VRPs, which are not packaged. Thus,
the proteasome cannot be involved solely in packaging and release of
viral progeny. Instead, it is likely that the impairment of WNV particle
release that we observed is due to a decrease in either (or both)
Fig. 6. Inhibition of proteasome results in impairment inWNV translation or genome replication, notWNV entry or unpackaging. HeLa cells were treated with either MG132 (panel A)
or PS1 (panel B) concurrent with or at various times post-WNV VRP infection and assayed for FLUC activity, WNV antigen expression and cell viability. Values are shown as percent of
mock and error bars represent standard deviation from the mean between two independent experiments.
Fig. 7. Proteasome inhibition impairs WNV particle release. Monolayers of HeLa cells
were infected with WNV for 1 h, the virus was removed and the indicated
concentrations of MG132 or PS1 were added to the infected cells. Twenty-four hours
post infection/treatment the supernatants were removed from the treated cells and the
titration of each sample was determined by IHC (see Materials and methods). Results
are shown as percent virus titer from mock-treated cells. Error bars represent the
standard deviation from the mean between three independent experiments.
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genome replication.
Consistent with our indirect assays (FLuc and ELISA), total levels of
WNV NS3, as measured by Western blot analysis, was dramatically
reduced following proteasome inhibitor treatment. The WNV NS2A–
NS3 complex serves as the viral protease and is required for the proper
processing of the viral polyprotein and subsequent genome replica-
tion. It is possible that the proteasome inhibitors, or the proteasome
itself, could have an effect on the protease activity of NS2A–NS3.
However, although there was a decrease in the expression of all
detectable viral proteins, there did not appear to be any abnormal
banding patterns associated with impaired protein processing from
proteasome inhibitor-treated cells (results not shown). This suggested
that it is unlikely that inhibiting the proteasome has a direct negative
effect on viral polyprotein processing.
Our IFA studies revealed a curious result. As expected, a decrease in
the expression of both NS1 and NS3 in the presence of the inhibitors
was readily detected; however, it appeared as though the effect on
NS1 expression was more pronounced than the effect on NS3. There
could be several reasons for this curious effect. It is possible that the
antibody against NS3 is more sensitive than the antibody against NS1,
particularly with MG132 treatment. It is also possible that viral
proteins have different turn-over rates. The location of NS1 within
secretory pathways of the infected cell may also concentrate the
antigen, making it more visible than NS3. Nevertheless, our data
clearly demonstrate a role for the proteasome at post-entry stages of
WNV infection, although we have not yet determined whether thereduction in antigen accumulation/expression is due to a direct
inhibition of viral translation or an inhibition of viral genome
replication (which would also reduce translational products).
The reason behind why the proteasome is important is not clear.
The ubiquitin–proteasome system is involved in a variety of normal
cellular processes, including signal transduction, transcriptional
82 F. Gilfoy et al. / Virology 385 (2009) 74–84regulation, the immune response and apoptosis, any of which could be
tied to WNV replication. Although WNV has been shown by several
groups to interfere with IFN-α/β signaling by preventing STAT1 phos-
phorylation (Guo et al., 2005; Scholle and Mason, 2005), this impair-
ment has not been shown to be achieved by the degradation of a
speciﬁc protein. More recently, Medigeshi et al. has demonstrated that
WNV induces the degradation of ATF6, a transcription factor as-
sociated with the ER, in a proteasome-dependent fashion (Medigeshi
et al., 2007). However, their studies were performed with liveWNV at
36 h post infectionwhile ours were performedwithWNV VRPs at 24 h
post infection. In our hands, WNV VRP infection does not cause
observable apoptosis at 24 h post infection. Associations between
proteasome inhibition of WNV VRP replication genome ampliﬁcation
and the degradation of ATF6 may be of interest to investigate.
Nevertheless, it is possible that WNV targets speciﬁc protein(s) to the
proteasome and that disrupting their degradation has a negative
impact on WNV genome ampliﬁcation. The identity of such proteins
will have to be investigated in more detail.
The role of the proteasome could also be linked to the formation of
defective ribosomal products (DRiPs). The process of translating the
sequences encoded by the viral (or cellular) genome to produce
functional proteins has many chances for the introduction of errors.
Mistakes include the addition of incorrect amino acids, early (or even
late) termination of the translated product or the improper folding or
splicing of proteins. These errors result in the formation of DRiPs
(Yewdell, 2002; Yewdell et al., 1996; Yewdell and Nicchitta, 2006). It is
expected that these incorrect products would be rapidly degraded by
the proteasome, as they could potentially interfere with the function
of the normal protein or other cellular processes. Thus, an accumula-
tion of WNV-generated DRiPs under conditions of rapid viral
polyprotein accumulation within replication complexes could inter-
fere with replication of the viral genome. The removal of these
damaged/defective products could be a reason why efﬁcient protea-
some function is required for WNV replication.
Materials and methods
Cell lines and their maintenance
Huh7 cells and HeLa cells were propagated in Dulbecco's Modiﬁed
Eagle's medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) and 1% antibiotic solution. Cells stably expressing Renilla
luciferase (RLuc) were used for all of these studies (see below), and
are referred to simply as HeLa or Huh7 cells throughout these studies.
BHK(VEErep/C⁎-E/pac) cells (Fayzulin et al., 2006), whichwere utilized
for WNV VRP preparations, were maintained in DMEM supplemented
with 10% FBS, 1% antibiotic solution and 10 μg/ml puromycin.
Generation of Renilla luciferase-expressing cell lines
RLuc-expressing cells were generated by infecting cell monolayers
with a vesticular stomatitis virus (VSV)-lentivirus pseudotype virus
expressing RLuc and blasticidin resistance (kindly provided by R
Davey, UTMB). Brieﬂy, monolayers of cell (plated in 6-well tissue
culture plates) were infected with the pseudotype virus. Twenty-four
hours post-infection, 2ug/ml of blasticidin was added to the media
and the cells were incubated at 37 °C. After approximately 2 weeks
under antibiotic selection, pools of the antibiotic-resistant cells were
harvested and propagated in normal growth media. To conﬁrm
integration of a functional RLuc gene, cells were tested for RLuc
activity as described below.
Virus and VRPs
The live WNV utilized in these studies was a low-passage virus
recovered from BHK cells transfected with a synthetic RNA derivedfrom an infectious cDNA clone of a human 2002 isolate from Texas
(Rossi et al., 2005). The virus recovered from BHK cells was passed
one time in Vero cells to obtain the stock that was used for all
experiments.
Two different WNV VRPs were utilized for the siRNA screen: VRPs
containing a WNV replicon expressing either a FLuc gene (C-FLuc2A
NS1-5) or a β-galactosidase gene (C-bgal2A NS1-5) followed by the
FMDV-2A coding region inserted between the C and NS1 encoding
regions in theWNV genome (Fayzulin et al., 2006). For the proteasome
inhibition studies, WNV hFLuc VRP was utilized instead of WNV FLuc
VRP. This VLP contained a replicon identical to C-FLuc2A NS1-5, except
that it contained a FLuc gene (derived from Promega) that had been
optimized for more efﬁcient expression in human cells. WNV VRPs
were generated as described previously (Fayzulin et al., 2006).
The titers of the stock virus and theWNVVRPswere determined by
focus formation assay in Vero cells as previously described (Gilfoy and
Mason, 2007). VEEV replicons encoding GFP and FLuc under control of
two separate subgenomic promoters (VEEre/Luc/GFP) packaged into
VRPs as described previously (Volkova et al., 2006) were kindly
provided by I. Frolov (UTMB).
Proteasome inhibition and VRP infection
Both MG132 (Calbiochem) and proteasome inhibitor 1 (PS1)
(Calbiochem) were initially diluted in DMEM++ to 20 μM and then
serially diluted 4- or 5-fold in DMEM++ supplemented with 1% DMSO
(diluent control). Fifty microliters of the inhibitor dilutions, 1% DMSO
or DMEM++ alone were added to monolayers of Huh7 or HeLa cells
(plated in 96 well plates) and incubated at 37 °C for approximately 2 h
and then infected with WNV VRPs. For VRP infections, 50 μl of WNV
hFLuc VRP was added to each well (on top of the proteasome
inhibitor) and incubated for 24 h at 37 °C. Since VRPs cannot spread
past the initial infected cell, it was not necessary to remove the VRPs
after infection. Unless otherwise noted, the inhibitors remained on the
cell monolayers for the entire length of the experiment.
siRNA transfection
Cells were transfected with Dharmacon plus Smartpool non-
targeting siRNA negative control (NEG siRNA; Dharmacon), Dharma-
con plus Smartpool PSMA1 siRNA (Dharmacon; pool of 4 sequences:
GCUAGACUGUUAUGUAAUU, GGGCAGGAUUCAUCAAAUU, CCAUUG-
GAAUUGUUGGUAA, GAUACCAACACAACGAUAU) or Dharmacon plus
Smartpool PSMA2 siRNA (Dharmacon; pool of 4 sequences:
GCAUAUAGGUUUGGUGUAC, ACACAAAGUAGAACCAAUU, GAAUGAGG-
GACGACCAUAU, CAAAUGGUGUGGUAUUAGC). Brieﬂy, siRNAs (to
achieve a 30 nM ﬁnal concentration) were incubated with 0.25 μl
DharmaFECT-1 (DF1; Dharmacon) transfection reagent diluted into
25 μl Dharmacon Cell Culture Reagent (DCCR; Dharmacon) for 10–
30 min at room temperature. The siRNA-DF1 complexes were added
to the wells (25 μl/well in 96-well plates) and 75 μl of cells at a
concentration of 1×105 cell/ml was added to the complexes and
incubated for approximately 72 h a 37 °C. Following the incubation
period, the transfected cells were infected with WNV VRPs as
described above. SiRNA transfections for all of the secondary
conﬁrmatory screens were performed as above. In the case of the
Ambion siRNA library, the transfection was similar to that described
above with the exception that the siRNAs, which were lyophilized
onto 96-well plates, were rehydrated in the plate with the DF1
diluted in DCCR.
Luciferase assays
Media from cell monolayers infected with WNV VRPs expressing
FLuc was removed at approximately 24 h post-infection. The cells
were mixed with luciferase substrate, a 1:5 mixture of Steady-glo
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magnesium acetate, 33mMDTT, 0.13mMEDTA and 0.1% Triton X-100)
and agitated for 30 s. Light output from the lysed cells was measured
in either a TR717 (Applied Biosystems) or a Centro XS3 LB 960
microplate luminometer (Berthold Technologies). To reduce costs, the
Ambion siRNA library and subsequent secondary screens were
assayed for FLuc activity using a self-prepared FLuc substrate as
described previously (Fayzulin et al., 2006). In some cases, immedi-
ately following measurement of FLuc activity, 50 μl of RLuc substrate
(100 mM EDTA, 10 mM Tris, 5 μg/ml coelenterazine (CTZ; NanoLight
Technologies)) was added directly to the wells. The plate was agitated
for 30 s and light output from the lysed cells was measured in one of
the luminometers described above.
Western blot analysis
Monolayers of siRNA-transfected cells (plated in 96-well plates)
were rinsed in phosphate-buffered saline solution (PBS) and
harvested in 100 μl of lysis buffer (0.1% Triton-X-100, 300 mM NaCl
and 50 mM Tris, pH 7.69). Protein concentrations were determined by
the Bio-Rad DC protein assay (Bio-Rad). Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transfer to a
Immobilon polyvinylidene diﬂuoride transfer membrane (Millipore)
as described previously (Gilfoy and Mason, 2007). Membranes were
probed with mouse anti-actin (Sigma), rabbit anti-PSMA2 (Santa
Cruz) or a goat anti-WNV NS3 (R and D Systems) followed by
incubation with a horseradish peroxidase (HRP)-conjugated second-
ary immunoglobulin (IgG) against the origin species for each of the
antibodies (KPL). HRP decorated bands were visualized as described
previously (Gilfoy and Mason, 2007).
ELISA
WNV antigen expression was measured by ELISA as previously
described (Rossi et al., 2005). Brieﬂy, ﬁxed cells were rehydrated in
blockingbuffer (PBS containing1%normal horse serum(NHS) and0.01%
Tween-20) and then incubated with an anti-WNV MHIAF polyclonal
antibody followed by incubation with an HRP-labeled goat anti-mouse
IgG (KPL). 3,3′,5,5′-Tetramethylbenzidine (TMB; Sigma) was added to
the plate and, following color development, the reactionwas stopped by
the addition of 1 M HCl. Absorbance was measured at 450 nm.
Cell viability assay
Cell viability was determined by a standard MTT assay. In short,
monolayers of treated cells were incubatedwith 10mg/mlmethylthia-
zolyldiphenyl-tetrazolium bromide (MTT; Sigma) solution for 3 h at
37 °C. Following incubation, the solution was removed and 100%
isopropanolwas added to solubilize themetabolizedMTT product. The
plates were then agitated for 15 min at room temperature, and
absorbance of the MTT product was measured at 560 nm.
WNV yield reduction assay
Yield reduction assays were performed as previously described
(Gu et al., 2006). Brieﬂy, monolayers of HeLa cells were infected with
WNV (MOI=0.05) for approximately 1 h at 37 °C followed by
treatment with dilutions of either MG132 or PS1 diluted in MEM++
containing 1% DMSO.. Cell supernatants harvested from the treated
cells were assayed for virus yield on Vero cell monolayers as
described (Gu et al., 2006).
Immunoﬂuorescence assay (IFA)
Monolayers of HeLa cells were treated with MG132 or PS1 and
infected with WNV hFLuc VLP as described above. Treated cellmonolayers were ﬁxed with 4% paraformaldehyde followed by
permeabilization with 0.1% Triton-X-100. The ﬁxed monolayers were
incubated in blocking buffer (2% bovine serum albumin, 5% normal
horse serum, 10 mM glycine in PBS) for 30 min and then probed using
the following monoclonal and polyclonal antibodies: mouse anti-NS1
(Eiji; Kobe University, Kobe, Japan), goat anti-NS3 (R and D Systems),
Alexa Fluor 488 goat anti-mouse IgG (Invitrogen) and Alexa Fluor 488
donkey anti-goat IgG (Invitrogen). Following secondary antibody
incubation, the cells were counterstained with DAPI (500 ng/ml) and
Alexa Fluor 594-conjugated phalloidin (R. Davey, UTMB) for nuclei and
actin ﬁlaments, respectively. The monolayers were thenmounted using
VectaShield (Vector Laboratories) and stained cellswere analyzedwith a
1.0 Zeiss LSM 510 UV META Laser Scanning Confocal Microscope at the
UTMB Infectious Disease and Toxicology Optical Imaging Core Facility.
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